s6y

BriaCell Therapeutics Corp.

Ticker
BCTX, BCTXL, BCTXZ
CIK
1610820
Industry
Pharmaceutical Preparations
Formerly
Ansell Capital Corp.

Financials 17

  1. 10-K Annual Report for period ending Jul 31, 2026
  2. 10-Q Quarterly Report for period ending Apr 30, 2026
  3. 10-Q Quarterly Report for period ending Jan 31, 2026
  4. 10-Q Quarterly Report for period ending Oct 31, 2025
  5. 10-K Annual Report for period ending Jul 31, 2025
  6. 10-Q Quarterly Report for period ending Apr 30, 2025
  7. 10-Q Quarterly Report for period ending Jan 31, 2025
  8. 10-Q Quarterly Report for period ending Oct 31, 2024
  9. 10-K Annual Report for period ending Jul 31, 2024
  10. 10-Q Quarterly Report for period ending Apr 30, 2024

All 17 financials filings

News 65

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 65 news filings

Ownership 45

  1. SC 13D/A Major Shareholders
  2. SC 13D/A Major Shareholders
  3. SC 13D/A Major Shareholders
  4. SC 13G/A Major Shareholders
  5. SC 13G Major Shareholders
  6. SC 13D/A Major Shareholders
  7. 4 Statement of changes in beneficial ownership of securities
  8. SC 13G/A Major Shareholders
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 45 ownership filings

Prospectus 39

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  3. S-1MEF A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1
  4. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  5. S-1 General form of registration statement for all companies including face-amount certificate companies
  6. DRSLTR Correspondence Related to Draft Registration Statement
  7. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  8. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  9. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  10. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses

All 39 prospectus filings

Proxies 8

  1. DEF 14A Definitive proxy statements
  2. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  3. DEF 14A Definitive proxy statements
  4. DEF 14A Definitive proxy statements
  5. DEF 14A Definitive proxy statements
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEF 14A Definitive proxy statements
  8. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

Other 150

  1. 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
  2. SCHEDULE 13G
  3. EFFECT Notice of Effectiveness
  4. 8-A12B Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)
  5. CERT Certification by an exchange approving securities for listing
  6. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  7. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  8. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  9. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  10. SCHEDULE 13G/A

All 150 other filings